An unpredictable tsunami is approaching!

According to World Health Organization, “Antimicrobial resistance (AMR) is the ability of a microorganism (like bacteria, viruses, and some parasites) to stop an antimicrobial (such as antibiotics, antivirals and antimalarials) from working against it” As a result, common life-saving treatments like caesareans will be potentially fatal, infections persist and may spread to others.

Read more


Superbugs are attacking from within hospitals!

Hospital-acquired infections or HAI’s are classified as infections a patient may contract while being treated for an unrelated issue in hospital or healthcare facility. Patients who contract HAI’s are often immune-compromised making them more susceptible to opportunistic bacteria causing infection and major complications to treatment, often causing patients to succumb to their illness.

Read more


Inventing ways to escape from ESKAPE!!

We at Polyamyna Nanotech Inc. (PNI), endeavor to develop next-generation antimicrobial technologies to prevent infections caused by deadly pathogens, especially ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens, eventually striving to address the global antimicrobial resistance (AMR) catastrophe.


Journey like this takes a strong team!

Ramesh Kumar Mani

Co-founder, PNI

Ramesh has obtained his Ph.D. from the Memorial University of Newfoundland, Canada. He possesses over twelve years of academic and industrial experience in developing innovative polymeric and bioceramic composites for tissue engineering and implant coating applications.

Kishan Gorityala

Co-founder, PNI

Kishan holds Ph.D from Nanyang Technological University, Singapore. He has rich research experience in antibacterial drug discovery. He successfully developed novel new antibiotic molecules, which overcome the resistance against Gram-negative bacteria.

Andrew Smith

Dr. Andrew Smith is a Family/ER physician and Associate Professor (Memorial University) with over 10 years clinical experience. Prior to medicine, Andrew completed a master’s degree in electrical engineering and currently holds a cross-appointment to the Faculty of Engineering and Applied Sciences. Andrew is

Carlos Bazan

Carlos Bazan, Assistant Professor of Civil Engineering & Engineering Chair in Entrepreneurship, Memorial University.  Dr. Bazan has extensive experience and expertise in business, finance and management.  Dr. Bazan has been on the board of directors of several companies and institutions. He has worke

latest news

  • Nov 2018: Our story published on CBC, NL  

  • Oct 2018: Polyamyna has been awarded InnovateNL Proof of Concept grant.

  • July 2018: Polyamyna awarded with MITACS Accelerate funding to carry out research and training.

  • May 2018: Polyamyna awarded with Embryo grant by Hacking Health, NL and NATI (Newfoundland and Labrador Association of Technology Industries) for the development of healthcare innovations.

  • April 2018: Polyamyna received NRC-IRAP grant for the development of highly-efficient antimicrobial technologies.

  • January 2018: Polyamyna has been accepted into Genesis’s Enterprise program.

Latest from the blog

05 Jun 19

Looking up at the night sky brings to mind flights of fancy and traveling through space on far off adventures. In reality, astronauts on the Intern

read more

01 May 19

The word ‘collateral’ elicits an unpleasant image of unintended damages in our minds. Sometimes though, the collateral effects could be

read more

02 Apr 19

In the early 2000s an intestinal superbug began quietly spreading through hospitals around the world causing a deadly form of diarrhea among immune

read more

02 Feb 19

A brand new area of antibiotic drug development is on the horizon as researchers recently unlocked the molecular mechanism controlling the mysterio

read more


  • No openings at this time

For more updates follow us on twitter